# Alerje

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alerje

- Industry: Software
- Headquarters: Detroit, US
- Website: www.alerje.com
- Total disclosed funding: $2M
- Latest round: Seed (Jul 28, 2023)
- Investors on record: 3

## About

Based in Michigan, US, and founded in 2016 by CEO Javier Evelyn, Alerje, Inc., a.k.a. Alerje operates as a software firm with a focus on offering a platform with a range of remote therapeutic management (RTM) tools for food allergies to facilitate the administration of OIT regimens and ensure that patients and physicians successfully complete them. In September 2023, Alerje, Inc. received USD 1 million in grant funding from The National Science Foundation.

Alerje offers an Oral Immunotherapy (OIT) management platform that simplifies the OIT process by keeping patients connected with their allergists, providing treatment-specific resources, tracking doses, and celebrating milestones. The company’s flagship product, the Omniject™ epinephrine auto-injector, attaches to a smartphone case for convenience, ensuring it is accessible and kept at an optimal temperature. The Omniject™ epinephrine auto-injector also provides automatic alerts to allergists, first responders, and a support network when activated.

The company plans to use its proceeds from September 2023 funding to expand the capabilities of its patent-pending AI digital platform as well as accelerate the manufacturing of its patented epinephrine auto-injector (EAI) solution.

## Funding rounds

- Seed, Jul 28, 2023, $1.9M — Chloe Capital, Solidea Capital
- Seed, Aug 21, 2019, $0.1M — Backstage Capital

## Investors

- Backstage Capital (https://capitalatlas.ai/funds/backstage-capital) — Seed
- Chloe Capital (https://capitalatlas.ai/funds/chloe-capital) — Seed
- Solidea Capital (https://capitalatlas.ai/funds/solidea-capital) — Seed